{"lc": {"ivermectin-can-kill-covid-19-within-48-hours-monash-university-study-finds": {"story_link": "https://www.thepharmaletter.com/article/ivermectin-can-kill-covid-19-within-48-hours-monash-university-study-finds", "user_code": "GOLD_7", "age_group": "21_30", "agreed": true, "close_date_time": "2021-10-18 12:36:26", "close_timestamp": 1637235386384, "created": "18/11/2021 11:36:28", "department": "Computing", "disability": false, "ease": 4, "environment": "production", "experiment_date_datepicker": "2021-11-18", "gender": "male", "id": "9ae31b44-918e-44fa-a938-838b64bd0fae", "open_date_time": "2021-10-18 12:28:28", "open_timestamp": 1637234908657, "story_date": "2020-04-21 00:00:00", "story_source": "tpl", "story_title": "Ivermectin can kill COVID-19 within 48 hours', Monash University study finds", "summary": "In 2020 a new drug called ivermectin has been identified and shown to the world. A researcher called Dr Kylie Wagstaff explained how it worked. The drug stops the reproduction of the virus in cells, hence inhibits replication. The factors on which the results depend have been discussed which includes factors in testing. For more information please refer to the following paper in the context of Antiviral Research explaining how the inhibition of virus replication works.", "task_condition": "viz", "task_key": "ivermectin-can-kill-covid-19-within-48-hours-monash-university-study-finds", "task_level": "post_graduate_ma_msc", "time_taken_in_seconds": 477727, "what": "a new drug called ivermectin has been examined. Dr Kylie Wagstaff made a statement about it stopping reproduction of the virus in cells and explained further how it works.", "when_happened": "few_years_ago", "where_location": "Probably UK", "who": "Dr Kylie Wagstaff", "why": "Because in 2020 many research labs where looking for a covid vaccine urgently to help reduce death through covid, and it seems a process has been identified to accomplish this."}, "challenges-expected-for-novavax-covid-19-vaccine-in-usa": {"story_link": "https://www.thepharmaletter.com/article/challenges-expected-for-novavax-covid-19-vaccine-in-usa", "user_code": "GOLD_7", "age_group": "21_30", "agreed": true, "close_date_time": "2021-10-18 12:58:5", "close_timestamp": 1637236685955, "created": "18/11/2021 11:58:07", "department": "Computing", "disability": false, "ease": 5, "environment": "production", "experiment_date_datepicker": "2021-11-18", "gender": "male", "id": "edcfdd01-a2f0-47e6-9921-236744f0f1ef", "open_date_time": "2021-10-18 12:47:10", "open_timestamp": 1637236030984, "story_date": "2021-06-23 00:00:00", "story_source": "tpl", "story_title": "Challenges expected for Novavax' COVID-19 vaccine in USA", "summary": "A new vaccine called \"Novavax's\" was found that has the properties of being easier to store and therefore is more adequate for distribution in less developed countries. It hass been tried with a testing population of 30,000  and has already proven to have an 90% overall efficacy rate, including alpha and beta variants. Other variants are currently being tested against it, which is an essential criterion for its success on battling covid on a global level. The vaccine will be submitted for approval int Q3 of this year, and the US has already preordered 100million doses which are planned to be supplied to other countries.", "task_condition": "text", "task_key": "challenges-expected-for-novavax-covid-19-vaccine-in-usa", "task_level": "post_graduate_ma_msc", "time_taken_in_seconds": 654971, "what": "A new vaccine that was found to be easier to store and therefore more suitable for the global battle against covid. ", "when_happened": "current_month", "where_location": "US, South Africa, UK, India, Mexico", "who": "Ms Jaser, Novavax, GAVI, US government,", "why": "The new vaccine significantly improved the fight against covid on a global level."}, "australian-gps-urged-to-prescribe-ivermectin-triple-therapy-to-fight-covid-19": {"story_link": "https://www.thepharmaletter.com/article/australian-gps-urged-to-prescribe-ivermectin-triple-therapy-to-fight-covid-19", "user_code": "GOLD_7", "age_group": "21_30", "agreed": true, "close_date_time": "2021-10-18 12:46:58", "close_timestamp": 1637236018942, "created": "18/11/2021 11:47:00", "department": "Computing", "disability": false, "ease": 5, "environment": "production", "experiment_date_datepicker": "2021-11-18", "gender": "male", "id": "f7b51277-f248-4436-ac7f-f4ebd8d85a31", "open_date_time": "2021-10-18 12:36:38", "open_timestamp": 1637235398869, "story_date": "2020-08-20 00:00:00", "story_source": "tpl", "story_title": "Australian GPs urged to prescribe ivermectin triple therapy to fight COVID-19", "summary": " Thomas Borody, a Sydney-based gastroenterologist that has acquired fame for his novel protocol for treating peptic ulsters has proposed a therapy based on ivermectin for COVID-19, a medication already approved by the FDA in another context and easy to access if prescribed as off-label treatment. He proposed this to the government but it appears that the Australian government is still focussed on finding a vaccine despite the possibility of his treatment being able to end the pandemic in Australia within two months, according to his personal estimation. He stresses the quality of Australia medical researches and proposes the idea that Australia could lead the world right now when deciding to use his protocols.", "task_condition": "text", "task_key": "australian-gps-urged-to-prescribe-ivermectin-triple-therapy-to-fight-covid-19", "task_level": "post_graduate_ma_msc", "time_taken_in_seconds": 620073, "what": " Thomas Borody, a Sydney-based gastroenterologist finding a new treatment for covid with already approved medicine which is however not stressed by the australian government.", "when_happened": "few_years_ago", "where_location": "Australia", "who": " Thomas Borody, a Sydney-based gastroenterologist ", "why": "The mentioned treatment could end the pandemic in Australia within two months."}, "japan-is-first-country-to-approve-covid-19-cocktail-ronapreve": {"story_link": "https://www.thepharmaletter.com/article/japan-is-first-country-to-approve-covid-19-cocktail-ronapreve", "user_code": "GOLD_7", "age_group": "21_30", "agreed": true, "close_date_time": "2021-10-18 12:28:21", "close_timestamp": 1637234901858, "created": "18/11/2021 11:28:23", "department": "Computing", "disability": false, "ease": 4, "environment": "production", "experiment_date_datepicker": "2021-11-18", "gender": "male", "id": "3ffd5403-88ad-497a-958c-6e8ee6243056", "open_date_time": "2021-10-18 12:15:47", "open_timestamp": 1637234147617, "story_date": "2020-07-21 00:00:00", "story_source": "tpl", "story_title": "Japan is first country to approve COVID-19 cocktail Ronapreve", "summary": "On 21/07/2020 the japanese labs \"casirivimab\" & \"imdevimab\" have found a new vaccine (covid cocktail) against covid infections. The pharma giant  \"SIX\" has announced that the antibody treatment developed was granted authorisation for use and the government has already secured supply. The cocktail reduces risk of hospitalisation and death from covid. Studies regarding its use for emerging variants including Delta are in talks. The products leads to suppression of aggravation and shortens the time of symptoms as well as the number of resolutions leading to higher number of outpatients as before. Dr Osamu Okuda executive vice president practicing in Japan has also given his statement regarding this matter.", "task_condition": "viz", "task_key": "japan-is-first-country-to-approve-covid-19-cocktail-ronapreve", "task_level": "post_graduate_ma_msc", "time_taken_in_seconds": 754241, "what": "a new covid cocktail was announced by a phama giant. It has already been tested, and authorised, which reduces hospitalisation & death risk and shortens time of symptoms.", "when_happened": "few_years_ago", "where_location": "Japan", "who": "Dr Osamu Okuda, Japan, unknown labs (maybe called casirivimab , imdevimab), unknown pharma giant (maybe SIX)", "why": "Because in 2020 many research labs where looking for a covid cocktail urgently to help reduce hospitalizations due to covid. It looks like in Japan they have found one and the government already authorized it."}}, "tb": {"pfizer": {"story_term": "pfizer", "user_code": "GOLD_7", "age_group": "21_30", "agreed": true, "close_date_time": "2021-10-18 13:55:16", "close_timestamp": 1637240116369, "created": "18/11/2021 12:55:18", "department": "Computing", "disability": false, "ease": 5, "environment": "production", "experiment_date_datepicker": "2021-11-18", "gender": "male", "id": "23cba8a0-277f-496c-81ad-b4715cdf34f5", "open_date_time": "2021-10-18 13:20:59", "open_timestamp": 1637238059531, "summary": "We heard a lot about the success of biotech companies, especially Pfizer, in recent months due to their prominence in having identified successful vaccines for covid treatment. What else are these companies doing on a strategic level to expand their business and how has the covid pandemic impacted the industry in general?\r\n\r\n\u00e2\u0080\u009cThe COVID-19 pandemic has been a stark reminder of the devastating impact of infectious diseases, highlighting the continuous need for new anti-infective therapies to treat both emerging and difficult to treat bacterial, viral and fungal infections,\u00e2\u0080\u009d said Angela Lukin, global president, Pfizer Hospital.\r\nThis might have positively impacted Pfizer's efforts to expand its business outside of covid related treatments.\r\n\r\nIn addition to its acquisition of Amplyx Pharmaceuticals in 2021 and latest acquisition of Arixa Pharmaceuticals, \"a company making a next-generation oral antibiotic, ARX-1796, that, if approved, would be one of the first new drugs of its kind in 35 years\", it is also going into license agreements such as with \"US biotech Celcuity (Nasdaq: CELC) to acquire exclusive rights to the US pharma giant\u00e2\u0080\u0099s gedatolisib, a Phase Ib pan-PI3K/mTOR inhibitor2 as well as \"Pyxis Oncology for the development and commercialisation of two antibody-drug conjugate (ADC) candidates and a license to Pfizer's ADC technology platform.\"\r\nAlso, \"China\u00e2\u0080\u0099s WuXi Biologics (HK: 2269) has entered into an equity agreement with US pharma giant Pfizer's (NYSE: PFE) China subsidiary to acquire its state-of-the-art biologics manufacturing facilities, as well as its labor force in Hangzhou, China.\"\r\n\r\nPotentially, the success of companies such as Pfizer and the general attention to biotech has also ignited the risk-taking willingness in the industry's m&a market in general.\r\nDespite Pfizer's takeover of Amplyx Pharmaceuticals there have been at least 11 other acquisitions this year reaching from a few million $ to acquire a final set of company shares to several billion. At least 11 mergers have been accomplished this year by mid may.\r\n\r\n\r\n\r\n", "task_condition": "text", "task_key": "pfizer", "task_level": "post_graduate_ma_msc", "time_taken_in_seconds": 2056838}, "astrazeneca": {"story_term": "astrazeneca", "user_code": "GOLD_7", "age_group": "21_30", "agreed": true, "close_date_time": "2021-10-18 13:20:42", "close_timestamp": 1637238042947, "created": "18/11/2021 12:20:44", "department": "Computing", "disability": false, "ease": 4, "environment": "production", "experiment_date_datepicker": "2021-11-18", "gender": "male", "id": "e94a4a33-d366-4d7a-964a-d44ff7b38567", "open_date_time": "2021-10-18 12:58:21", "open_timestamp": 1637236701460, "summary": "The financial impact of covid on drug producers - seeing the good in bad times.\r\n\r\nAstraZeneca has developed one of the most important vaccines in human history and has therefore , understandably, been one of the most discussed companies in the past months. The company has gained a lot of investor trust and a spectacular financial sheet which allows it to take further risks with other medication outside of covid.  This can be seen in the fact that excluding the contribution from the COVID-19 vaccine \"the company delivered significant revenue growth of 15% in the quarter to $7,320 million\".\r\n\r\nAstraZeneca has no better means to invest in rare disease medication. \"Rare diseases is also a high-growth therapy area with a high level of unmet medical need. With over 7,000 rare diseases currently known about, just 5% currently have FDA-approved treatments.\"\r\nWith its new revenue and investor trust generated from covid related vaccines, AstraZeneca is able to diversify its portfolio by buying for example American rare disease specialist Alexion Pharmaceuticals (Nasdaq: ALXN) at $39 billion.\r\n\r\n\"The acquisition, which would add a portfolio of five approved therapies as well as a pipeline of more than twice that number of candidates, has already been approved by the US Federal Trade Commission (FTC).\"\r\n\r\nMore investment into these areas and higher investor trust in the company can lead to higher outcomes in finding effective treatments for rare diseases, something that would have been more difficult with the lack of trust, interest and agglomerated capital in the company before covid.\r\n\r\n\r\n", "task_condition": "viz", "task_key": "astrazeneca", "task_level": "post_graduate_ma_msc", "time_taken_in_seconds": 1341487}}}